Lupin plans to launch 30 drugs in the US market in FY17

06 Jun 2016 Evaluate

Lupin is planning to launch around 30 drugs in the US market in FY17. The drug major is awaiting US Food and Drug Administration (USFDA) approval for around 160 products. The Mumbai-based company has filed the same to the US health regulator from its Indian as well as overseas facilities.

Lupin has a portfolio of 124 products in the US market. The company, which faced around 12 inspections from the USFDA last year, including a repeat inspection of its Goa plant, has been trying to achieve a ‘holistic transformation’ at its facilities.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

 

Lupin Share Price

2079.50 -33.45 (-1.58%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×